Patents by Inventor Kevin Thewlis
Kevin Thewlis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11180479Abstract: The present invention relates to novel compounds of general formula (I) wherein R1 to R4 and n have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.Type: GrantFiled: October 5, 2018Date of Patent: November 23, 2021Assignee: HAPLOGEN GMBHInventors: Wolfgang Fischl, Christopher John Yarnold, Patricia Leonie Amouzegh, Kevin Thewlis, Jon Shepherd, Mark Anthony Kerry
-
Publication number: 20200239446Abstract: The present invention relates to novel compounds of general formula (I) wherein R1 to R4 and n have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.Type: ApplicationFiled: October 5, 2018Publication date: July 30, 2020Inventors: Wolfgang FISCHL, Christopher John YARNOLD, Patricia Leonie AMOUZEGH, Kevin THEWLIS, Jon SHEPHERD, Mark Anthony KERRY
-
Patent number: 7919507Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: wherein the substituent variables are as defined herein, and their use as pharmaceuticals.Type: GrantFiled: October 26, 2007Date of Patent: April 5, 2011Assignee: SmithKline Beecham LimitedInventors: Clive Leslie Branch, Steven Coulton, Amanda Johns, Christopher Norbert Johnson, Roderick Alan Porter, Geoffrey Stemp, Kevin Thewlis
-
Patent number: 7741329Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: wherein the substituent variables are as defined herein, and their use as pharmaceuticals.Type: GrantFiled: October 29, 2007Date of Patent: June 22, 2010Assignee: SmithKline Beecham LimitedInventors: Clive Leslie Branch, Steven Coulton, Amanda Johns, Christopher Norbert Johnson, Roderick Alan Porter, Geoffrey Stemp, Kevin Thewlis
-
Publication number: 20090093478Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: wherein the substituent variables are as defined herein, and their use as pharmaceuticals.Type: ApplicationFiled: October 26, 2007Publication date: April 9, 2009Inventors: Clive Leslie BRANCH, Steven Coulton, Amanda Johns, Christopher Norbert Johnson, Roderick Alan Porter, Geoffrey Stemp, Kevin Thewlis
-
Publication number: 20090029986Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: wherein the substituent variables are as defined herein, and their use as pharmaceuticals.Type: ApplicationFiled: October 29, 2007Publication date: January 29, 2009Inventors: Clive Leslie BRANCH, Steven Coulton, Amanda Johns, Christopher Norbert Johnson, Roderick Alan Porter, Geoffrey Stemp, Kevin Thewlis
-
Publication number: 20090012073Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: wherein the substituent variables are as defined herein, and their use as pharmaceuticals.Type: ApplicationFiled: October 26, 2007Publication date: January 8, 2009Inventors: Clive Leslie BRANCH, Steven Coulton, Amanda Johns, Christopher Norbert Johnson, Roderick Alan Porter, Geoffrey Stemp, Kevin Thewlis
-
Patent number: 7432270Abstract: This invention relates to N-aroyl cyclic amine derivatives and their use as orexin antagonists wherein: Y represents a bond, oxygen, or a group (CH2)n, wherein n represents 1, 2 or 3; m represents 1, 2, or 3; p represents ) or 1; X is NR, wherein R is H or (C1-4)alkyl; Ar1 is aryl, or a mono or bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S; any of which may be optionally substituted; A2 represents phenyl or a 5- or 6-membered heterocyclyl group containing up to 3 heteroatoms selected from N, O and S, wherein the phenyl or heterocyclyl group is substituted by R1 and further optional substituents; or Ar2 represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing up to 3 heteroatoms selected from N, O and S; R1 represents hydrogen, optionally substituted (C1-4)alkoxy, halo, cyano, optionally substituted (C1-6)alkyl, optionally substituted phenyl, or an optionally substituted 5- or 6-membered heterocyclyl group containing up to 4 hetType: GrantFiled: May 2, 2002Date of Patent: October 7, 2008Assignee: SmithKline Beecham p.l.c.Inventors: Clive Leslie Branch, Steven Coulton, Amanda Johns, Christopher Norbert Johnson, Roderick Alan Porter, Geoffrey Stemp, Kevin Thewlis
-
Publication number: 20080045532Abstract: Compounds of formula (I) and salts are provided: along with pharmaceutical compositions, uses in medicine, e.g., treating disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment.Type: ApplicationFiled: March 19, 2007Publication date: February 21, 2008Inventors: Stephen Harrison, Kevin Thewlis, Simon Ward
-
Publication number: 20070270471Abstract: This case discloses compounds of formula (I) wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; B is —N(R4)— or —O—; A and D, which may be the same or different, are —C(R5)2—; each R2, which may be the same or different, is C1-6alkyl, halogen, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro or amino; n is 0, 1 or 2; R3 is C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro, amino, —(CH2)pNR3aSO2R3b, —(CH2)pNR3a(C?O)R3b, —(CH2)pNR3a(C?O)N(R3c)2, —(CH2)p(C?O)R3d, —(CH2)pSO2R3e, phenyl or heterocyclyl, wherein when R3 is phenyl or heterocyclyl, it is optionally substituted by one or more groups independently selected from: C1-6alkyl, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro, amino, —(CH2)pNR3aSO2R3b, —(CH2)pNR3a(C?O)R3b, —(CH2)pNR3a(C?O)N(R3c)2, —(CH2)p(C?O)R3d and —(CH2)pSO2R3e; where R3a and each R3c, which may be the same or different, is hydrogen or C1-6alkyl; R3b and R3e are C1-6alkyl or haloC1-6aType: ApplicationFiled: August 5, 2005Publication date: November 22, 2007Applicant: GLAXO GROUP LIMITEDInventors: Kevin Thewlis, Simon Ward
-
Publication number: 20070203218Abstract: This case discloses compounds of formula (I) wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; R2 and R3, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano or amino; each R4, which may be the same or different, is C1-6alkyl, halogen, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro or amino; p is 0, 1 or 2; each R5, which may be the same or different, is C1-6alkyl, halogen, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro or amino; q is 0,1 or 2; R6 is ?NR6aSO2R6b, —NR6aC(?O)R6b, —NR6a(C?O)N(R6c)2, —(C?O)R6d, —CH2NR6aSO2R6b, —CH2NR6aC(?O)R6b, CH2NR6a(C?O)N(R6c)2 or —CH2(C?O)R6d; where R6a and each R6c, which may be the same or different, is hydrogen or C1-6alkyl; R6b and R6d are C1-6alkyl or haloC1-6alkyl; or R6a and R6b, or R6a and R6c, together with the interconnecting atoms, may form a 5- or 6-membered ring; n is 1 or 2; and R7 and R8, which may be the same or different, areType: ApplicationFiled: August 5, 2005Publication date: August 30, 2007Inventors: Kevin Thewlis, Simon Ward
-
Publication number: 20070161638Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof, are disclosed: wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; R2 and R3, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, amino, monoC1-4alkylamino or diC1-4alkylamino; each R4, which may be the same or different, is C1-6alkyl, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro, amino, monoC1-4alkylamino or diC1-4alkylamino; p is 0, 1 or 2; n is 1 or 2; R5 and R6, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, amino, monoC1-4alkylamino or diC1-4alkylamino; and Het is thienyl, pyridyl, pyrimidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, pyrrolyl, quinolyl, thiazolyl or furyl, each of which may be substituted by one or more groups independently selected from the list consistingType: ApplicationFiled: August 5, 2005Publication date: July 12, 2007Inventors: Daniel Bradley, Kevin Thewlis, Simon Ward
-
Patent number: 6943160Abstract: This invention relates to morpholine derivatives of formula (I) and their use as antagonists of orexin receptors.Type: GrantFiled: November 22, 2001Date of Patent: September 13, 2005Assignee: SmithKline Beecham plcInventors: Clive Leslie Branch, Christopher Norbert Johnson, Alexander B. Smith, Geoffrey Stemp, Kevin Thewlis
-
Patent number: 6939871Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein Ar is phenyl, naphthyl, a monocyclic heteroaromatic group or a bicyclic heteroaromatic group, said Ar group being optionally substituted by 1-4 substituents, which may be the same or different, and which are selected from the group consisting of: halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C1-6alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C1-6alkoxy, arylC1-6alkoxy, C1-6alkylthio, C1-6alkoxyC1-6-alkyl, C3-7cycloalkylC1-6alkoxy, C1-6alkanoyl, C1-6alkoxycarbonyl, C1-6alkylsulfonyl, C1-6alkylsulfinyl, C1-6alkylsulfonyloxy, C1-6alkylsulfonylC1-6alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC1-6alkyl, C1-6alkylsulfonamido, C1-6alkylamido, C1-6alkylsulfonamidoC1-6alkyl, C1-6alkylamidoC1-6alkyl, arylsulfonamido, arylcarboxamido, alkylsulfonamidoC1-6alkyl, arylcarboxamidoC1-6alkyl, aroyl, arolC1-6alkyl, arylC1-6alkanoyl, a group R<3>OCO(CH2)s, R<3>CON(R&Type: GrantFiled: October 22, 2001Date of Patent: September 6, 2005Assignee: SmithKline Beecham p.l.c.Inventors: Christopher Norbert Johnson, Harshad Kantilal Rami, Geoffrey Stemp, Kevin Thewlis, Mervyn Thompson, Antonio Keuok Keong Vong
-
Publication number: 20050176724Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein A is optionally substituted phenyl, indolyl, quinolinyl, quinazolinyl, indazolyl or isoquinolinyl; X is carbon, Y is CH and ? is a double bond; or X is CH, Y is CH2 or oxygen and ? is a single bond; or X is nitrogen, Y is CH2 and ? is a single bond; R1 is halogen, cyano, nitro, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, C3-7heterocyclylC1-6alkyl, C3-7heterocyclyl C1-6alkoxy; a is 0, 1, 2, 3 or 4; R2 is either: halogen, —CN, an optionally substituted C3-7cycloalkyl, an optionally substituted aryl or an optionally substituted C-linked 3-7 membered heterocyclic group; or a group -(Z)b-B wherein: (i) Z is oxygen, CH2, C?O, SO2 or C?N—OR3 wherein R3 is hydrogen or C1-6alkyl; b is 1, 2, or 3; and B is hydrogen, C1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or NR4R5 wherein R4 and R5 are independently hydrogen, C1-6alkyl, C3-7cycloalkyl, C1-6alkanoyl, fluoroC1-6alkanoyl, C1-6alkylsulfonyl, fluoroC1-6alkylsulfonyl, carbamoyl or C1-6Type: ApplicationFiled: February 17, 2003Publication date: August 11, 2005Inventors: Sean Flynn, Paul Smith, Kevin Thewlis, Simon Ward
-
Publication number: 20050107410Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein: A is optionally substituted phenyl, naphthyl, indolyl, quinolinyl, quinazolinyl, indazolyl, isoquinolinyl or benzofuranyl; X is carbon, Y is CH and is a double bond; or X is CH, Y is CH2 or oxygen and is a single bond; or X is nitrogen, Y is CH2 and is a single bond; is halogen, hydroxy, cyano, C1-6alkyl, haloC1-6alkyl or C1-6alkoxy; a is 0, 1, 2, 3 or 4; R2 and R3, together with the nitrogen atom to which they are attached, form a nitro group or an optionally substituted 3 to 7 membered heterocyclic group, or R2 and R3 are independently hydrogen, aroyl, C1-6alkyl, C1-6alkanoyl, fluoroC1-6alkanoyl, C1-6alkylsulfonyl, fluoroC1-6alkylsulfonyl, carbamoyl, C1-6alkylcarbamoyl, arylC1-6alkyl or a group CO(CH2)bNR4R5 wherein b is 1, 2, 3 or 4; and R4 and R5 are independently hydrogen or C1-6alkyl, or R4 and R5, together with the nitrogen atom to they are attached, form part of an optionally substituted 3Type: ApplicationFiled: February 17, 2003Publication date: May 19, 2005Inventors: Paul Smith, Kevin Thewlis, Antonio Vong, Simon Ward
-
Publication number: 20040143115Abstract: This invention relates to N-aroyl cyclic amine derivatives and their use as orexin antagonists 1Type: ApplicationFiled: November 5, 2003Publication date: July 22, 2004Inventors: Clive Leslie Branch, Steven Coulton, Amanda Johns, Christopher Norbert Johnson, Roderick Alan Porter, Geoffrey Stemp, Kevin Thewlis
-
Publication number: 20040063704Abstract: The present invention relates to novel compounds of formula (1) or a pharmaceutically acceptable salt thereof, wherein Ar is phenyl, naphthyl, a monocyclic heteroaromatic group or a bicyclic heteroaromatic group, said Ar group being optionally substituted by 1-4 substituents, which may be the same or different, and which are selected from the group consisting of: halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C1-6alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C1-6alkoxy, arylC1-6alkoxy, C1-6alkylthio, C1-6alkoxyC1-6-alkyl, C3-7cycloalkylC1-6alkoxy, C1-6alkanoyl, C1-6alkoxycarbonyl, C1-6alkylsulfonyl, C1-6alkylsulfinyl, C1-6alkylsulfonyloxy, C1-6alkylsulfonylC1-6alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC1-6alkyl, C1-6alkylsulfonamido, C1-6alkylamido, C1-6alkylsulfonamidoC1-6alkyl, C1-6alkylamidoC1-6alkyl, arylsulfonamido, arylcarboxamido, arylsullonamidoC1-6alkyl, arylcarboxamidoC1-6alkyl, aroyl, arylC1-6alkyl, arylC1-6alkanoyl, a group R3OCO(CH2)s, R3CON(R4)(CH2)s, R3R4NCO(Type: ApplicationFiled: October 16, 2003Publication date: April 1, 2004Inventors: Christopher Norbert Johnson, Harshad Kantilal Rami, Geoffrey Stemp, Kevin Thewlis, Mervyn Thompson, Antonio Keuok Keong Vong
-
Publication number: 20040058921Abstract: This invention relates to morpholine derivatives of formula (I) and their use as antagonists of orexin receptors.Type: ApplicationFiled: October 9, 2003Publication date: March 25, 2004Inventors: Clive Leslie Branch, Christopher Norbert Johnson, Alexander B. Smith, Geoffrey Stemp, Kevin Thewlis
-
Patent number: 6677354Abstract: Disclosed are compounds of formula (I): wherein: Y represents a group (CH2)n, wherein n represents 0, 1 or 2; R1 is phenyl, naphthyl, a mono or bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S; or a group NR3R4 wherein one of R3 and R4 is hydrogen or optionally substituted (C1-4)alkyl and the other is phenyl, naphthyl or a mono or bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S, or R3 and R4 together with the N atom to which they are attached form a 5 to 7-membered cyclic amine which has an optionally fused phenyl ring; any of which R1 groups may be optionally substituted; R2 represents phenyl or a 5- or 6-membered heteroaryl group containing up to 3 heteroatoms selected from N, O and S, wherein the phenyl or heteroaryl group is substituted by R5, and further optional substituents; or R2 represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing up to 3 heteroatoms selected from N, OType: GrantFiled: December 16, 2002Date of Patent: January 13, 2004Assignee: SmithKline Beecham p.l.c.Inventors: Clive Leslie Branch, Christopher Norbert Johnson, Geoffrey Stemp, Kevin Thewlis